Project Grant HT94252410967
Award Date
10/1/24
Completion Date
9/30/27
Dollars Obligated
$451K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Washington, DC 20057, USA
Similar Awards
This three-year, $1.335 million Project Grant from the Department of the Army Medical Command, under the Military Medical Research and Development program (CFDA 12.420), will support biomarkers research of response to combination cabozantinib and nivolumab treatment in advanced renal cell carcinoma. The grantee, Dana-Farber Cancer Institute, will analyze whole exome sequencing, RNA sequencing, and clinical outcome data to identify genetic alterations and gene expression signatures that impact...
This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $1,130,469 to Yale University to uncover the tumor-immune microenvironmental determinants of immunotherapy response in renal cell carcinoma through ex vivo patient-derived models. The research aims to transform health care for Service Members and the American public through innovative and impactful research investigating medical solutions for the battlefield....
This Project Grant award was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to the University of Texas Southwestern Medical Center. The $1,312,000 grant, with a period of performance from July 1, 2024 to June 30, 2028, will support research on biomarkers and mechanisms of acquired resistance to immunotherapy for renal cell carcinoma. This work aims to improve understanding and treatment of this form of kidney cancer, which is a...
The federal Project Grant award of $1,009,054.00 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The award supports research aimed at "Discovery and Therapeutic Targeting of Endogenous Retroviruses in Clear Cell Renal Cell Carcinoma" at Yale University over the period of September 1, 2025 to August 31, 2029. The research project seeks to advance biomedical knowledge and develop innovative treatments for this form of...
This $769,073 Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research to define and target cancer cell-intrinsic vulnerabilities in renal cell carcinoma. The grant was awarded to the Royal Institution for the Advancement of Learning / McGill Office of Sponsored Research Division, a private university affiliated with McGill University in Montreal, Canada. The research will be conducted from August 1, 2024...
This federal Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) provides $592,859.00 to the University of Wisconsin System for a research project titled "GENE EXPRESSION ANALYSIS OF CIRCULATING TUMOR CELLS: A NEXT-GENERATION BIOMARKER TO PREDICT IMMUNOTHERAPY RESPONSE IN METASTATIC CLEAR CELL RENAL CELL CARCINOMA". The project aims to advance scientific understanding and develop new diagnostic...
This Project Grant award in the amount of $322,371.00 from the Defense Health Agency (DHA) was provided to Yale University on May 15, 2024 under the Military Medical Research and Development program (CFDA 12.420). The award supports the research project "OVERCOMING RESISTANCE TO IMMUNE CHECKPOINT INHIBITOR-BASED THERAPIES FOR RENAL CELL CARCINOMA" with a planned completion date of May 14, 2027. The goal of this grant is to advance scientific understanding and therapeutic approaches for...
This Project Grant award of $1,106,902.00 was provided by the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420). The award supports research at the University of Texas Southwestern Medical Center in Dallas, Texas to "delineate tumor-immune contexture that shapes clear cell renal cell carcinoma (ccRCC) metastatic progression and response to immunotherapy." The 3-year project aims to advance the understanding of the tumor-immune...
The Johns Hopkins University will receive $334,652 under a three-year Project Grant award from the Defense Health Agency to characterize the prognostic and predictive role of immune cell population changes induced by neoadjuvant PD-1 inhibition in clear cell renal cell carcinoma. The grant is funded through the Military Medical Research and Development program (CFDA 12.420), which supports biomedical research to transform military and public health care through innovative solutions for...
The federal Project Grant award titled "UNLOCKING THE POTENTIAL OF IMMUNE CHECKPOINT INHIBITORS IN THE PAPILLARY RENAL CELL CARCINOMA SETTING" is being provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The $879,847 award, effective from August 1, 2025 to July 31, 2029, supports advanced biomedical research conducted by ST Michael's Hospital, a non-profit hospital in Toronto, Canada, to investigate the use of immune...